SeaStar Medical Holding Corporation announces the issuance of U.S. Patent No. 11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device, SCD, to treat subjects with inflammatory conditions and to process activated leukocytes and platelets. The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response. “This patent significantly fortifies our intellectual property portfolio and is highly supportive of our strategy to validate our technology’s application across multiple high-value clinical indications in which hyperinflammation plays a role,” said Eric Schlorff, CEO of SeaStar Medical. “Regardless of its source, uncontrolled hyperinflammation can lead to vital organ damage and even death. Our SCD therapy works to selectively target the most highly activated cells responsible for inflammation to bring activated cells into a reparative state. This can stop the potential damage of over-activated cells and potentially reverse the damage they cause.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICU:
- SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
- SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
- SeaStar Medical enrolls 12 subjects in NEUTRALIZE-AKI trial
- SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
- SeaStar Medical announces formation of Scientific Advisory Board